This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAboutAboutHow TRUMENBA WorksTru Patient StoriesAre Your Patients Protected?CDC RecommendationsDosingEfficacy & SafetyEfficacy & SafetySafety Profile and TolerabilityImmunogenicity & PersistenceSupport & OrderSupport & OrderEventsMaterialsVideosWelcome to TruSupportOrdering & InventoryCoverage & ReimbursementPatient Adherence
Prescribing InformationIndicationMedical Information
CDC RecommendationsCDC recommendations support MenB vaccination for 16-year-olds1,2*CDC guidelines support MenB vaccination for 16 year olds1,2*

In October 2024, ACIP voted to align the MenB vaccine schedule as 2 doses (at 0 and 6 months when used as a 2-dose series) for healthy adolescents and young adults aged 16 through 23 years to provide short-term protection against most strains of MenB. The preferred age for MenB vaccination is 16 through 18 years. The decision to vaccinate should be made based on shared clinical decision-making.5,6

The Affordable Care Act mandates insurance coverage for all vaccinations administered in accordance with ACIP recommendations. Health care providers should contact their individual plan to determine specific coverage and reimbursement requirements and adoption timeframes.7 MenB vaccines are available through the Vaccines for Children program.8

 More information from ACIP Find out more Loading More information from CDC Find out more Loading CDC's Vaccine Information Statement on MenB Download LoadingIndividuals at increased risk for MenB should be vaccinated, according to ACIP2

ACIP recommends certain persons aged ≥10 years who are at increased risk for meningococcal disease should receive MenB vaccine. These persons include:

  • Persons who are in a MenB outbreak situation or at increased risk for meningococcal disease
  • Persons with persistent complement component deficiencies§
  • Persons with anatomic or functional asplenia, including sickle cell disease
  • Microbiologists routinely exposed to isolates of Neisseria meningitidis

The American Academy of Pediatrics

Encourages pediatricians to discuss the availability of MenB vaccines with families, and the decision should be documented if the vaccine is not administered9

 What is MenB?

MenB is uncommon, but potentially fatal, and early symptoms may seem like the flu10,11

The American Academy of Pediatrics

 Learn more about MenB LoadingBased on shared clinical decision-making.1If at increased risk of disease or based on discussion with patient’s family.1Concomitant administration did not significantly increase local or systemic events compared with TRUMENBA alone.12,13Including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or who are taking complement inhibitors.2ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; fHbp=factor H binding protein; HPV=human papillomavirus vaccine; MenACWY=quadrivalent (serogroups A, C, W, Y) meningococcal conjugate vaccine; MenB=serogroup B meningococcal disease; MMR=measles, mumps, rubella vaccine; Tdap=tetanus, diphtheria, pertussis vaccine. Contact your Pfizer Sales Representative or call a Vaccine Specialist at ​​​1-800-666-7248.References:1. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025. Updated November 21, 2024. Accessed January 13, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf 2. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1-41. 3. TRUMENBA® (Meningococcal Group B Vaccine). Prescribing information. Pfizer; 2024. 4. Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345-350. 5. Centers for Disease Control and Prevention. Meningococcal vaccine recommendations. Updated October 24, 2024. Accessed January 13, 2025. https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/index.html 6. Schillie S. Introduction to MenB-4C (Bexsero) Interval and Dosing Label Change. Presented at: Advisory Committee on Immunization Practices; October 24, 2024; Atlanta, GA. Accessed January 13, 2025. https://www.cdc.gov/acip/downloads/slides-2024-10-23-24/04-mening-Schillie-508.pdf 7. The Center for Consumer Information & Insurance Oversight. Affordable Care Act implementation FAQs. Updated September 10, 2024. Accessed January 13, 2025. https://www.cms.gov/cciio/resources/fact-sheets-and-faqs/aca_implementation_faqs12 8. Meningococcal disease: meningococcal vaccination. Centers for Disease Control and Prevention. Updated June 26, 2024. Accessed January 13, 2025. https://www.cdc.gov/vaccines/vpd/mening/index.html 9. American Academy of Pediatrics. Recommendations for serogroup B meningococcal vaccine for persons 10 years and older. Pediatrics. 2016;138(3):1-7. 10. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403. 11. Meningococcal disease symptoms and complications. Centers for disease control and prevention. Last reviewed August 30, 2024. Accessed January 13, 2025. https://www.cdc.gov/meningococcal/symptoms/index.html 12. Senders S, Bhuyan P, Jiang Q, et al. Immunogenicity, tolerability, and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J. 2016;35(5):548-554. 13. Muse D, Christensen S, Bhuyan P, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35(6):673-682.
Pfizer TruSupport
  • Ordering options
  • Patient coverage confirmation
  • Essential tools
  • Resources for your practice
 Find out about TruSupportLoading
TRUMENBA clinical studies

TRUMENBA was the FIRST MenB vaccine with proven protection against diverse strains.3

 See the dataLoading
The science behind TRUMENBA

Only TRUMENBA targets both subfamilies, A and B, of fHbp.3

 See the scienceLoading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-TRU-USA-3203
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367

INDICATION
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Important Safety Information
  • Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
  • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
  • Vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%) 
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Safety and effectiveness have not been established in pregnant women
Indication
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Please see full Prescribing Information.